Table 2.
Univariate and multivariate analyses
| Characteristic | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Number of patients | 5-year OS (%) | P | HR | 95% CI | P | |
| Histology | - | - | 0.009 | - | - | 0.000 |
| SCC | 61 | 34.4 | - | 1 (Ref) | - | - |
| AC | 48 | 45.8 | - | 1.275 | 0.743 – 2.186 | 0.378 |
| Others | 20 | 20.0 | - | 4.201 | 2.024 – 8.721 | 0.000 |
| pT classification | - | - | 0.000 | - | - | 0.000 |
| T1 | 20 | 70.0 | - | 1 (Ref) | - | - |
| T2 | 66 | 45.5 | - | 1.201 | 0.338 – 2.393 | 0.833 |
| T3 | 19 | 10.5 | - | 2.280 | 0.634 – 8.197 | 0.207 |
| T4 | 24 | 4.2 | - | 4.974 | 1.451 – 17.052 | 0.011 |
| pN classification | - | - | 0.000 | - | - | 0.042 |
| N0 | 67 | 53.7 | - | 1 (Ref) | - | - |
| N1 | 21 | 33.3 | - | 1.381 | 0.608 – 3.137 | 0.440 |
| N2 | 31 | 12.9 | - | 4.160 | 1.341 – 12.905 | 0.014 |
| N3 | 10 | 0 | - | 4.508 | 1.397 – 14.548 | 0.012 |
| pTNM stage | - | - | 0.000 | - | - | 0.125 |
| I | 48 | 70.8 | - | 1 (Ref) | - | - |
| II | 29 | 24.1 | - | 1.216 | 0.327 – 4.519 | 0.770 |
| III | 52 | 11.5 | - | 2.158 | 0.859 – 5.418 | 0.102 |
| CD3 | - | - | 0.002 | - | - | - |
| Low | 82 | 25.6 | - | 1 (Ref) | - | - |
| High | 47 | 55.3 | 1.205 | 0.642 – 2.264 | 0.562 | |
| CD8 | - | - | 0.000 | - | - | - |
| Low | 72 | 48.6 | - | 1 (Ref) | - | - |
| High | 57 | 21.1 | 2.154 | 1.323 – 3.509 | 0.002 | |
| IL-2 | - | - | 0.000 | - | - | - |
| Low | 49 | 18.4 | - | 1 (Ref) | - | - |
| High | 80 | 47.5 | - | 1.940 | 1.104 – 3.408 | 0.021 |
OS: Overall survival; HR: Hazard ratio; P: Significance level for log-rank test; 95% CI: 95% confidence interval; Ref.: Reference group; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; TNM: Tumor; lymph node, metastasis; IL-2: Interleukin-2.